BE1016292A3 - Verbinding en gebruik bij behandeling. - Google Patents

Verbinding en gebruik bij behandeling. Download PDF

Info

Publication number
BE1016292A3
BE1016292A3 BE2004/0472A BE200400472A BE1016292A3 BE 1016292 A3 BE1016292 A3 BE 1016292A3 BE 2004/0472 A BE2004/0472 A BE 2004/0472A BE 200400472 A BE200400472 A BE 200400472A BE 1016292 A3 BE1016292 A3 BE 1016292A3
Authority
BE
Belgium
Prior art keywords
treatment
connection
pharmaceutically acceptable
epicholecalciferol
bishomo
Prior art date
Application number
BE2004/0472A
Other languages
English (en)
Dutch (nl)
Inventor
Luciano Adorini
Enrico Colli
Original Assignee
Bioxell Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0322395A external-priority patent/GB0322395D0/en
Priority claimed from GB0325598A external-priority patent/GB2407499B/en
Priority claimed from GB0416876A external-priority patent/GB0416876D0/en
Application filed by Bioxell Spa filed Critical Bioxell Spa
Application granted granted Critical
Publication of BE1016292A3 publication Critical patent/BE1016292A3/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BE2004/0472A 2003-09-24 2004-09-24 Verbinding en gebruik bij behandeling. BE1016292A3 (nl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0322395A GB0322395D0 (en) 2003-09-24 2003-09-24 Methods for treating bladder dysfunction and related compounds and compositions
GB0325598A GB2407499B (en) 2003-11-03 2003-11-03 Vitamin D3 analogue for use in the treatment of BPH
GB0416876A GB0416876D0 (en) 2004-07-29 2004-07-29 Compound and use in treatment

Publications (1)

Publication Number Publication Date
BE1016292A3 true BE1016292A3 (nl) 2006-07-04

Family

ID=34229055

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2004/0472A BE1016292A3 (nl) 2003-09-24 2004-09-24 Verbinding en gebruik bij behandeling.

Country Status (11)

Country Link
EP (1) EP1673096A1 (https=)
JP (2) JP2007506699A (https=)
CN (1) CN100488511C (https=)
BE (1) BE1016292A3 (https=)
BR (1) BRPI0404050A (https=)
CH (1) CH698144B1 (https=)
EA (1) EA010240B1 (https=)
FR (1) FR2859910B1 (https=)
NL (1) NL1027109C2 (https=)
NZ (1) NZ535531A (https=)
WO (1) WO2005027923A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090227651A1 (en) * 2004-10-05 2009-09-10 Kissei Pharmaceutical Co., Ltd. Preventive and/or therapeutic agent for urine collection disorder accompanying lower urinary tract obstruction
PL1806136T3 (pl) * 2004-10-06 2012-04-30 Kissei Pharmaceutical Kompozycja medyczna do zapobiegania przejściu na leczenie operacyjne łagodnego rozrostu gruczołu krokowego
US20100009949A1 (en) * 2006-03-24 2010-01-14 Bioxell S.P.A. Novel method
US8221803B1 (en) 2007-06-25 2012-07-17 OncoNatural Solutions, Inc. Composition for prostate health
US20120164240A1 (en) 2010-12-22 2012-06-28 Audino David Lawrence Enriched a. blitoides compositions and uses thereof
US20170049834A1 (en) * 2015-08-18 2017-02-23 Golden Biotechnology Corporation Benign prostatic hyperplasia add-on therapy
FR3063906B1 (fr) * 2017-03-20 2025-12-12 Pf Medicament Utilisation de l'oleoresine de copaifera dans les pathologies de la prostate
CN120960385A (zh) * 2025-08-01 2025-11-18 上海交通大学医学院附属第九人民医院 5α–还原酶降解分子及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0808833A2 (en) * 1996-05-23 1997-11-26 F. Hoffmann-La Roche Ag Vitamin D3 analogs
WO1998029123A1 (en) * 1996-12-30 1998-07-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin d analogues
WO2003034961A1 (en) * 2001-10-23 2003-05-01 Euro-Celtique, S.A. Terazosin transdermal device and methods
WO2003047595A1 (en) * 2001-12-03 2003-06-12 Novacea, Inc. Pharmaceutical compositions comprising active vitamin d compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW403735B (en) * 1995-11-22 2000-09-01 Hoffmann La Roche 25-hydroxy-16-ene-26, 27-bishomo-cholecalciferol
CA2289209C (en) * 1997-05-16 2006-07-25 Women & Infants Hospital Cyclic ether vitamin d3 compounds, 1.alpha. (oh) 3-epi-vitamin d3 compounds and uses thereof
US5872113A (en) * 1997-05-16 1999-02-16 Syntex (U.S.A.) Inc. Fluorinated vitamin D3 analogs
US6255501B1 (en) * 1999-04-26 2001-07-03 Hoffman-La Roche Inc. Process for preparing antiosteoporotic agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0808833A2 (en) * 1996-05-23 1997-11-26 F. Hoffmann-La Roche Ag Vitamin D3 analogs
WO1998029123A1 (en) * 1996-12-30 1998-07-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin d analogues
WO2003034961A1 (en) * 2001-10-23 2003-05-01 Euro-Celtique, S.A. Terazosin transdermal device and methods
WO2003047595A1 (en) * 2001-12-03 2003-06-12 Novacea, Inc. Pharmaceutical compositions comprising active vitamin d compounds

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANON: "BioXell commences phase II trial of BXL - 628", DRUG NEWS & PERSPECTIVES, (MAR 2003) VOL. 16, NO. 2, PP. 122-122. PUBLISHER: PROUS SCIENCE, SA, PO BOX 540, PROVENZA 388, 08025 BARCELONA, SPAIN. ISSN: 0214-0934., March 2003 (2003-03-01), XP001205124 *
BRANDL MICHAEL ET AL: "Chemical reactivity of Ro-26-9228, 1alpha-fluoro-25-hydroxy-16,23E-di ene-26,27-bishomo-20-epi-cholecalciferol in aqueous solution.", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 92, no. 10, October 2003 (2003-10-01), pages 1981 - 1989, XP002315528, ISSN: 0022-3549 *
CRESCIOLI C ET AL: "Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia", EUROPEAN JOURNAL OF ENDOCRINOLOGY, vol. 150, no. 4, April 2004 (2004-04-01), pages 591 - 603, XP009043025, ISSN: 0804-4643 *
http://www3.interscience.wiley.com/cgi-bin/abstract/104550629/ABSTRACT, Published Online 30 Jul 2003 *
MEALY N E: "BXL-628", DRUGS OF THE FUTURE 2004 SPAIN, vol. 29, no. 6, 2004, pages 629, XP009043214, ISSN: 0377-8282 *

Also Published As

Publication number Publication date
EA010240B1 (ru) 2008-06-30
EP1673096A1 (en) 2006-06-28
NZ535531A (en) 2006-03-31
NL1027109A1 (nl) 2005-03-29
BRPI0404050A (pt) 2005-06-14
WO2005027923A1 (en) 2005-03-31
CN100488511C (zh) 2009-05-20
NL1027109C2 (nl) 2005-05-03
CN1615891A (zh) 2005-05-18
FR2859910B1 (fr) 2006-04-28
JP2007506699A (ja) 2007-03-22
EA200401100A1 (ru) 2005-04-28
JP2009035559A (ja) 2009-02-19
HK1085373A1 (zh) 2006-08-25
CH698144B1 (fr) 2009-05-29
FR2859910A1 (fr) 2005-03-25

Similar Documents

Publication Publication Date Title
MY164900A (en) Use of an alpha-adrenoceptor antagonist in combination with a muscarinic antagonist in the manufacture of a medicament for treating the lower urinary tract symptoms associated with benign prostatic hyperplasia
LU93321I2 (fr) Ibrutinib, ou un sel pharmaceutiquement acceptable de celui-ci
WO2008046083A3 (en) Use of oxindole compounds as therapeutic agents
MXPA03010085A (es) Composiciones y su uso en la hiperplasia.
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2007149406A3 (en) Modified coagulation factor ix polypeptides and use thereof for treatment
TW200505434A (en) Therapeutic treatment
WO2006071274A3 (en) Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer’s disease
TW200509949A (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
WO2008046082A3 (en) Use of heterocyclic compounds as therapeutic agents
WO2004064735A3 (en) Treatment of benign prostatic hyperplasia
WO2003011117A3 (en) Methods and compositions for treating and preventing distal bowel lesions
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
BE1016292A3 (nl) Verbinding en gebruik bij behandeling.
TN2009000135A1 (en) Use of modified cyclosporins
WO2003090753A8 (en) Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention
WO2008044782A3 (en) Combination drug
GB201115757D0 (en) Formulation for the treatment of benign prostate hyperplasia
UA56965U (ru) Средство для лечения и профилактики доброкачественной гиперплазии предстательной железы, простатита, импотенции, бесплодия и paka предстательной железы
MX2009009230A (es) Uso de silodosina en una administracion diaria para tratar hiperplasia prostatica benigna.
AU2003219573A1 (en) Controlled release formulation of tamsulosin or pharmaceutically acceptable salts thereof for treatment of the signs and symptoms of benign prostatic hyperplasia
MX2007005980A (es) Composiciones para el tratamiento de infecciones oticas.
PT1713438E (pt) Sabonete medicinal
GEP20104911B (en) Medicinal agent for preventing progression of apoptotic and jugulating necrotic changes in the organism tissues
WO2007077454A3 (en) A therapeutic composition comprising an inhibitor of an hsp 90 protein

Legal Events

Date Code Title Description
RE Patent lapsed

Effective date: 20100930